The first clinical study on melanoma was carried out by Baldi and colleagues [51], who reported significant HtrA1 upregulation in primary tumours compared with that in metastases, and suggested that HtrA1 expression could be an indicator of disease progression. Here, HTRA1 is linked to neoplasm.